Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 SeraCare Acquires KPL | Contract Pharma

What are you searching for?

Sign in
Breaking News

SeraCare Acquires KPL

Expands diagnostic offerings

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

SeraCare Life Sciences has acquired Kirkegaard & Perry Laboratories (KPL), a provider of antibodies and related reagents for the diagnostic and life sciences markets. The acquisition has allowed SeraCare to expand its portfolio of products designed to help diagnostic researchers develop innovative in vitro diagnostic assays through both off-the-shelf products and custom antibody design, according to a company statement.

“The diagnostics industry requires high quality materials for use in assay design, development of components for regulated kits, and validation of these products as they move from the laboratory to the clinic,” said Charles Mamrak, chief executive officer of SeraCare. “SeraCare strives to facilitate its customers’ product development efforts, allowing researchers to focus on the science, specifically the design and launch of cutting-edge new assays. The addition of KPL will enable SeraCare to more fully meet the needs of these diagnostic researchers, fueling their innovation by providing reliable and qualified materials for use in these assays.”

KPL’s portfolio of products includes high quality immunochemicals for in vitro diagnostics, including primary and secondary antibodies as well as reagents and kits targeting ELISA, western blotting, immunohistology, protein labeling, nucleic acid labeling, sample preparation, protein purification, and recombinant protein detection and analysis. These products will support SeraCare’s expansion from its core strength of providing biological products and control materials for infectious disease, women’s health, and genetic testing into oncology, autoimmune, allergy and companion diagnostics.

Financial terms were not disclosed, but SeraCare secured funding for the acquisition and refinanced its existing debt with Madison Capital Funding and BB&T Capital Partners. Kirkland & Ellis LLP provided legal advice to SeraCare for the transaction.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics